507 related articles for article (PubMed ID: 18668241)
1. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
4. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Zangari M; Tricot G; Polavaram L; Zhan F; Finlayson A; Knight R; Fu T; Weber D; Dimopoulos MA; Niesvizky R; Fink L
J Clin Oncol; 2010 Jan; 28(1):132-5. PubMed ID: 19901114
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma.
Kessler P; Pour L; Gregora E; Zemanova M; Penka M; Brejcha M; Adam Z; Bacovsky J; Fenclova M; Frankova H; Hausdorf P; Walterova L; Heinzova V; Holikova M; Krejci M; Kubackova K; Langrova E; Maisnar V; Meluzinova I; Stavarova Y; Straub J; Scudla V; Gumulec J; Ullrychova J; Hajek R;
Klin Onkol; 2011; 24(4):281-6. PubMed ID: 21905619
[TBL] [Abstract][Full Text] [Related]
6. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
[TBL] [Abstract][Full Text] [Related]
10. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
[TBL] [Abstract][Full Text] [Related]
11. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
16. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
19. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Hussein MA
Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
